He’s an entrepreneur, a TV star, a billionaire—and now, he’s a guest on Independent Rx Forum. On our latest episode, we got the one-and-only Mark Cuban to sit down with NCPA CEO Douglas Hoey to talk about Cost Plus Drugs, his latest attempt at disruption aimed squarely at sidestepping pharmacy benefit managers’ middleman role.
In the podcast Cuban is joined by Cost Plus Drug General Counsel Erin Albert and well-known industry analyst Antonio Ciaccia. Click here to listen.
NCPA
